拉米夫定联合胸腺肽α1治疗慢性乙型肝炎疗效分析  

Efficacy Analysis of Lamivudine Combined with Thymosin α1 in Treatment of Chronic Hepatitis B

作　　者：王莹[1] 那琳琳[1] 

机构地区：[1]哈尔滨二四二医院,黑龙江哈尔滨150060

出　　处：《哈尔滨医药》2011年第6期412-413,共2页Harbin Medical Journal

摘　　要：目的比较拉米夫定联合胸腺肽α1与单独应用拉米夫定治疗慢性乙型肝炎(CHB)患者的临床疗效。方法选择52例CHB患者,采用完全随机、对照的方法分成两组。联合治疗组26例,应用拉米夫定100 mg/d,口服,观察疗程18月,胸腺肽α1 1.6 mg/次,皮下注射,2次/周,连续6月;对照组仅给拉米夫定100 mg/d,口服,观察疗程疗18月。结果治疗后12月、18月时,联合治疗组HBV-DNA转阴率、HBeAg、抗-HBe转换率及ALT复常率与拉米夫定组有明显差异性(P<0.05)。结论拉米夫定联合胸腺肽α1治疗CHB患者的疗效优于单用拉米夫定。Objective To evaluate the efficacy of Lamivudine alone or combined with Thymosin α1 in treatment of chronic hepatitis B（CHB）.Methods The 52 patients with CHB were randomly divided into combination therapy group（26 cases）and Lamivudine group（26 cases）.The combination therapy group was treated with Lamivudine,100 mg/d,orally,for 18 months,and Combining Thymosin α1,1.6 mg,two times each week,subcutaneously,for 6 mouths.Lamivudine group was treated with lamivudine,100 mg/d,orally,for 18 months.Results After 12 and 18 months of treatment,there were significant differences in the rate of serum HBV DNA turned to negative,HBeAg/anti-HBe sero-conversion rate and ALT recovery rate between combination therapy group and Lamivudine group（P0.05）.Conclusion The combination of Lamivudine and Thymosin α1 has better effect than the monotherapy of Lamivudine in patients with CHB.

关 键 词：肝炎 乙型 慢性米夫定 胸腺肽Α1 联合治疗 

分 类 号：R512.6[医药卫生—内科学]